Mekinist (trametinib) | Friends of Cancer Research

You are here

Mekinist (trametinib)

Sponsor: 
Novartis Pharmaceuticals Corp.
Indication: 
In combination with dabrafenib for the adjuvant treatment of patients with stage III melanoma with a BRAF V600E or V600K mutation, as detected by and FDA-approved test, and involvement of lymph node(s), following complete resection
Category: 
Year: 
2017
Date: 
Oct 23rd
FDA Status: 
FDA Approval
Approval Date: 
Apr 30th
Approval Year: 
2018